Twist Bioscience

Anthropic names Twist Bioscience as an independent evaluator for protein-design tests using the AI models Claude Opus 4.8 and Mythos Preview. In the third quarter, Twist recorded its 14th consecutive revenue record and is aiming to reach EBITDA break-even in the near term. The physical validation of AI-generated DNA strengthens the company’s position as a sought-after partner in the biotech sector. » More on finanzen.net

Twist Bioscience’s stock marked a 52-week high at $143.10 and traded near that level, lifting market capitalization to about $8.94 billion. For Q3 2026 the company reported revenue of $118.4 million, beating expectations, but posted an adjusted loss of $0.56 per share. InvestingPro rates the stock as highly overvalued and notes high volatility (beta 2.16); additionally, an anthorpic-related collaboration and skepticism from Scorpion Kapital have prompted mixed investor reactions. » More on de.investing.com

Twist Bioscience has filed a prospectus supplement to register the resale of shares that Invenra is entitled to under a stock purchase agreement dated February 11, 2026. The filing is made as part of a registration rights agreement between the companies; Invenra can thus resell the registered shares. TWST stock is trading near its 52-week high; the company reported Q3 2026 revenue of $118.4 million (above expectations) and an adjusted loss of $0.56 per share. Twist was also selected for a protein-design campaign led by Anthropic, although short seller Scorpion Capital questions the significance of that partnership. » More on de.investing.com